<div id="readability-page-1"><div>By Katherine Hamilton Johnson &amp; Johnson's Rybrevant Faspro was approved as a treatment for people with lung cancer by the Food and Drug Administration. Rybrevant Faspro was approved across all indications for subcutaneous administration for patients with epidermal growth factor receptor-mutated non-small cell lung cancer, J&amp;J said Wednesday. The approval is based on the results of a Phase 3 trial, which met both co-primary pharmacokinetic endpoints. Patients treated showed longer duration of response, improved progression-free survival and longer overall survival. Rybrevant Faspro enables a simpler, shorter administration time for a first-line combination regime when combined with Lazcluze. Rybrevant is approved in the U.S. across four indications in that specific type of lung cancer. Write to Katherine Hamilton at katherine.hamilton@wsj.com (END) Dow Jones Newswires12-17-25 1920ET</div></div>

强生

强生的 Rybrevant Faspro 获得 FDA 批准，用于治疗表皮生长因子受体突变的非小细胞肺癌。该批准基于成功的第三阶段临床试验结果，显示出改善的生存率和反应持续时间。Rybrevant Faspro 与 Lazcluze 联合使用时提供了更简单的给药方式，并在美国获得了四项适应症的批准

强生公司获得美国食品药品监督管理局批准其肺癌治疗方案